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Background. A novel translational pharmacology investigation was conducted by combining an in vitro efficacy target with mu-
cosal tissue pharmacokinetic (PK) data and mathematical modeling to determine the number of doses required for effective human
immunodeficiency virus (HIV) preexposure prophylaxis (PrEP).
Methods. A PK/pharmacodynamic (PD) model was developed by measuring mucosal tissue concentrations of tenofovir, em-
tricitabine, their active metabolites (tenofovir diphosphate [TFVdp] and emtricitabine triphosphate [FTCtp], respectively), and com-
peting endogenous nucleotides (dATP and dCTP) in 47 healthy women. TZM-bl and CD4+ T cells were used to identify 90%
effective concentration (EC90) ratios of TFVdp to dATP and FTCtp to dCTP (alone and in combination) for protection against
HIV. Monte-Carlo simulations were then performed to identify minimally effective dosing strategies to protect lower female genital
tract and colorectal tissues.
Results. The colorectal TFVdp concentration was 10 times higher than that in the lower female genital tract, whereas concen-
trations of endogenous nucleotides were 7–11 times lower. Our model predicted that ≥98% of the population achieved protective
mucosal tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine. However, a minimum adherence
to 6 of 7 doses/week (85%) was required to protect lower female genital tract tissue from HIV, while adherence to 2 of 7 doses/week
(28%) was required to protect colorectal tissue.
Conclusions. This model is predictive of recent PrEP trial results in which 2–3 doses/week was 75%–90% effective in men but
ineffective in women. These data provide a novel approach for future PrEP investigations that can optimize clinical trial dosing
strategies.
Keywords. HIV; antiretroviral; translational medicine; dose response; population pharmacokinetics-pharmacodynamics; quan-
titative pharmacology; preexposure prophylaxis.
A fixed-dose, combination tablet of tenofovir disoproxil fuma-
rate (TDF) 300 mg and emtricitabine (FTC) 200 mg received
Food and Drug Administration approval for human immuno-
deficiency virus (HIV) preexposure prophylaxis (PrEP) on the
basis of findings from 2 trials. Partners PrEP demonstrated 75%
efficacy among heterosexual serodiscordant couples [1], and
iPrEx demonstrated 44% efficacy among men who have sex
with men (MSM) and transgender women [2]. However, 2
subsequent trials investigating daily TDF, with or without
FTC, in high-risk women (FEM-PrEP and VOICE) failed to
demonstrate efficacy [3, 4]. Analysis of plasma drug concentra-
tions from these studies revealed that only 24%–30% of these
women exhibited evidence of recent product use. Yet in a cohort
of male participants from the successful iPrEx trial, only 28%
had evidence of recent product use [2]. Subsequent analysis re-
vealed that drug exposure consistent with 2–3 doses/week
achieved 75%–90% protection in MSM [5, 6]. These findings
pose an important question: why are adherence requirements
for effective PrEP less strict for men?
We recently demonstrated that exposure of TDF’s active me-
tabolite (tenofovir diphosphate [TFVdp]) is 100-fold higher in
colorectal tissue relative to female genital tract (FGT) tissue [7].
This may partially explain different adherence requirements in
men and women. Another potential factor is the concentration
of host cells’ endogenous 2′deoxynucleotides analogs, deoxya-
denosine triphosphate (dATP) and deoxycytidine triphosphate
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(dCTP). The active intracellular phosphorylated metabolites of
TFV and FTC (TFVdp and emtricitabine triphosphate
[FTCtp]) compete with dATP and dCTP for incorporation
into the proviral DNA strand to terminate chain elongation
[8]. Since dATP and dCTP can be modulated by proinflamma-
tory signaling molecules [9, 10] and because mucosal tissues
may have environments with altered inflammatory states, it is
possible that endogenous nucleotides differ between cervical,
vaginal, and colorectal tissue and contribute to altered antiviral
efficacy of TFVdp and FTCtp. To investigate mechanisms of ef-
ficacy within FGT and colorectal tissues, we used a quantitative
systems pharmacology approach to predict the probability of
protection against HIV with varying patterns of adherence to
TDF, FTC, and TDF plus FTC.
METHODS
Study Design
We conducted a phase 1, single-dose, pharmacokinetic (PK) in-
vestigation of TDF and FTC at 50%, 100%, or 200% of the treat-
ment dose (clinical trials registration NCT01330199). Blood
specimens were collected at baseline and over 48 hours, and
each participant provided 1 cervical, vaginal, and colorectal tissue
sample at 6, 12, 24, or 48 hours after dose receipt. Drug concen-
trations were quantified in plasma specimens, peripheral blood
mononuclear cells (PBMCs), and tissue specimens. The study
was conducted in accordance with good clinical practices, and
all participants provided written informed consent before study
entry. Details about the clinical trial, sample processing, and an-
alytical methods are provided in the Supplementary Methods.
In Vitro Concentration Versus Response
TZM-bl reporter cells (NIH AIDS Reagent Program, German-
town, MD) [11, 12] and human CD4+ T cells were used to de-
termine HIV type 1 (HIV-1) infection in the presence of TFV
and FTC. A total of 100 000 TZM-bl cells were plated in 6-well,
flat-bottomed culture plates in 2 mL of Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine serum and
antibiotics to match the experimental conditions for drug
quantification where >100 000 cells were needed. Cells were in-
cubated in TFV (0.05–35 µM), FTC (0.03–30 µM), or their
combination (NIH AIDS Reagent Program) for 24 hours at
37°C. A total of 5 µL of HIV-1JR-CSF (NIH AIDS Reagent Pro-
gram; multiplicity of infection [MOI], 0.006) and 5 µL of
DEAE-dextran were added to each well. This HIV-1JR-CSF
dose was selected to ensure that infection, as measured by
luminescence, was within linear range. After 48 hours, cells
were lysed with 500 µL of GloLysis Buffer (Promega, Madison,
Wisconsin), and relative light units were measured using a Lu-
ciferase Assay System kit (Promega) on a Veritas Microplate
Luminometer (Turner Biosystems, Sunnyvale, California). In-
fectivity was normalized to infection in the absence of drug
and reported as percentage inhibition.
PBMCs isolated from buffy coats obtained from the
New York Blood Center (Long Island City, New York) were
sorted for CD4+ T lymphocytes, using an EasySep negative se-
lection kit (Stemcell Technologies, Vancouver, Canada). Typi-
cal cell yields using this kit demonstrate approximately 96%
purity and >90% viability. CD4+ T cells were stimulated for
48 hours in Roswell Park Memorial Institute (RPMI) medium
supplemented with 10% fetal bovine serum, antibiotics, phyto-
hemagglutinin (PHA; 5 µg/mL), and interleukin 2 (10 units/
mL). A total of 1 × 106 CD4+ T cells/mL were resuspended
and incubated in PHA-free RPMI medium as prepared above
and with either TFV (0.3–10 µM) or FTC (0.03–30 µM) for
24 hours. Pseudotyped virus was generated using NL4-3.Luc.
R-.E-backbone (NIH AIDS Reagent Program) [13, 14] and
transfected with env expression plasmid from HIV-1JR-CSF,
using X-tremeGENE HP (Roche Life Science, Indianapolis, In-
diana). Virions were concentrated 10-fold using Lenti-X Con-
centrator (Clontech Laboratories, Mountain View, California).
Cells were incubated for 48 hours in 25 µL of pseudotyped
virus (MOI, 1) then lysed with 100 µL of GloLysis Buffer. Infec-
tion was reported as described above.
Ratios of the cellular active metabolite concentration to the
endogenous nucleotide concentration were quantified with an
identical set of uninfected TZM-bl or CD4+ cells. Cells were
harvested at the time of HIV-1 challenge (24 after incubation
in the drug), washed, counted, lysed in 70% methanol/water,
and stored at −80°C for TFVdp, FTCtp, dATP, and dCTP
quantification.
The following reagents were obtained through the AIDS Re-
agent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, National Institutes of Health: TZM-bl,
from Dr John C. Kappes, Dr XiaoyunWu, and Tranzyme; HIV-
1JR-CSF, from Dr Irvin Chen; and pNL4-3.Luc.R
–.E–, from Dr
Nathaniel Landau.
PK Analysis
Calculation of the area under curve over 48 hours (AUC0–48h)
was performed individually, using the linear up/log down trap-
ezoidal rule for plasma and PBMCs, with WinNonlin v6.3
(Pharsight, Sunnyvale, California). The AUC0–48h was calculat-
ed using sparsely sampled data and the linear trapezoid rule for
tissue. Concentrations below the limit of detection or quantifi-
cation were imputed as 10% or 50% of the lower limit of quan-
tification, respectively.
Monte Carlo simulations were performed with a popula-
tion PK model built using the clinical trial concentration
data and NONMEMv7.4, ICON plc. Simulations were per-
formed for the first 10 doses and at steady state with dosing
intervals representing 1–7 doses/week. Time to steady-state
was defined as the first dose at which the 24-hour concentra-
tion (Ctrough) was within 10% of the simulated steady-state
Ctrough.
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Statistical Analysis
Dose proportionality was assessed in tissues across a 4-fold dos-
ing range to assist with PK modeling, using the Holder method
[15], and was declared if the 90% confidence interval (CI)
around the regression line slope (b^1) for the log-transformed
dose versus concentration fit within 0.64–1.36. This analysis
was conducted using Rv2.14 [16]. On the assumption of a per-
centage coefficient of variation of ≤45%, 8 women/dosing level
provided 83% power to declare dose proportionality. Between-
tissue comparisons of endogenous nucleotides were made using
1-way analysis of variance with the Bonferroni correction. De-
scriptive and comparative statistics were performed with
SASv9.3 (SAS Institute, Cary, North Carolina).
Exposure versus response was described for the in vitro
data using Emax regression (E0 fixed to 0, Emax fixed to 1,
E = Response, MR =molar ratio) for active metabolite:endogenous
nucleotide versus fraction inhibition of HIV-1 infection, as follows:
E ¼ E0 þ MR
H  Emax
MRH þ EC50H
ð1Þ
Negative values were fixed at 0. Synergy was assessed with the
following pharmacodynamic (PD) interaction model (c^ ) [17]
for the ratios of TFVdp to dATP concentrations and FTCtp
to dCTP concentrations in TZM-bl cells by fixing the 50%
effective concentration (EC50) and Hill slope (H) parameters
from equation 1:
E ¼
TFV
c EC50;TFV
 
HTFV þ FTC
c EC50;FTC
 
HFTC þ TFV
c EC50;TFV
 
HTFV  FTC
c EC50;FTC
 
HFTC
1þ TFV
c EC50;TFV
 
HFTV þ FTC
c EC50;FTC
 
HFTC þ TFV
c EC50;TFV
 
HTFV  FTC
c EC50;FTC
 
HFTC
ð2Þ
A 3-dimensional goodness-of-fit plot was generated and vi-
sually inspected to evaluate model predictions for bias. The
final fitted parameters (HTFV, HFTC, EC50TFV, EC50FTC, and
c^ ) were used to predict percentage inhibition from simulated
concentrations, with an efficacy target of 90%.
RESULTS
Participant Demographic Characteristics and Safety
Between April 2012 and August 2013, 49 healthy female vol-
unteers gave consent for the clinical trial. Participant de-
mographic characteristics are summarized in Table 1 and
stratified by treatment arm. Eight participants were enrolled
into each dosing group except TDF 300 mg, in which 1 partic-
ipant was unable to provide samples and was withdrawn and
replaced. Samples from 1 participant who received FTC 200
mg were not analyzed because of improper storage. Single
doses of TDF and FTC up to 200% of the licensed treatment
dose were well tolerated with no adverse events above grade 1
severity (Table 1).
Drug Concentrations and Dose Proportionality
Figure 1 depicts the area under the concentration-time curve
versus dose for extracellular concentrations and intracellular
metabolite concentrations in plasma, PBMCs, and tissues.
Table 2 summarizes dose proportionality statistics. Plasma
FTC concentrations increased dose proportionally. Plasma
TFV concentrations did not meet dose proportionality criteria
but exhibited dose linearity. PBMC concentrations of TFVdp
but not FTCtp increased dose proportionally. Since no notable
difference was observed between cervical and vaginal tissue
concentrations, they were averaged for subsequent analyses. A
single composite tissue AUC0–48h was calculated for each dosing
group and tissue type. Only FGT FTC concentrations increased
dose proportionally.
Median dose-adjusted AUC0–48h for TFV and TFVdp were
10–45 times higher in colorectal tissue (38.5 µg*hr*g−1 and
2046.5 pmol*hr*g−1, respectively), compared with FGT tissue
(0.83 µg*hr*g−1 and 188 pmol*hr*g−1, respectively). Although
median dose-adjusted FTC AUC0–48h was higher in colorectal
Table 1. Demographic Characteristics and Adverse Events
Variable
Tenofovir
Disoproxil
Fumarate (n = 25)
Emtricitabine
(n = 24)
Demographic characteristic
Age, y 27 (22.75–31.25) 22 (21–27)
Weight, kg 67.4 (60.4–76.8) 62.8 (57.7–72.3)
BMIa 24.1 (21.6–26.9) 22.5 (20.8–26.5)
Race
White 16 (64) 18 (75)
African American 8 (32) 4 (16.7)
Asian American 1 (4) 1 (4.2)
American Indian 0 (0) 1 (4.2)
Adverse event
Headache 1 (4) 5 (20.8)
Nausea 2 (8) 0
Early menses 1 (4) 0
Fatigue 1 (4) 0
Bowel disturbances 1 (4) 1 (4.2)
Elevated transaminase levels 0 1 (4.2)
Pelvic cramps 0 1 (4.2)
Postnasal drip 0 1 (4.2)
Vaginal dryness 0 1 (4.2)
Ear infection 1 (4) 0
Viral pharyngitis 1 (4) 0
Data are median value (interquartile range) or no. (%) of subjects.
a Body mass index (BMI) is calculated as the weight in kilograms divided by the height in
square meters.
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Figure 1. Dose proportionality in blood plasma, peripheral blood mononuclear cells (PBMCs), and mucosal tissues. Mean (±standard error) areas under curve over 48 hours
(AUC0–48h) for tenofovir (TFV; A), TFV diphosphate (TFVdp; B), emtricitabine (FTC; C), and FTC triphosphate (FTCtp; D) in female genital tract (FGT) tissue (Δ), colorectal tissue
(○), and plasma (□) for tenofovir and emtricitabine and in PBMCs for TFVdp and FTCtp (□).
Table 2. Dose Proportionality Statistics
Matrix Analyte Slope, b^1
a (90% CI) r2 P
Dose
Proportionalb
Plasma Emtricitabine 0.84 (.70–.97) 0.85 <.0001 Yes
Plasma Tenofovir 0.77 (.63–.92) 0.80 <.0001 No
PBMC FTCtp 0.19 (.012–.37) 0.13 .09 No
PBMC TFVdp 1.07 (.91–1.24) 0.83 <.0001 Yes
FGT Emtricitabine 0.91 (.78–1.05) NAc Yes
FGT FTCtp 0.12 (−.29 to .53) NAc No
FGT Tenofovir 0.77 (.46–1.09) NAc No
FGT TFVdp 0.93 (.14–1.72) NAc No
Colorectal Emtricitabine 1.24 (−.29 to 2.77) NAc No
Colorectal FTCtp 0.22 (−.23 to .67) NAc No
Colorectal Tenofovir 2.15 (.31–4.00) NAc No
Colorectal TFVdp 0.35 (−1.10 to 1.80) NAc No
Abbreviations: CI, confidence interval; FGT, female genital tract; FTCtp, emtricitabine triphosphate; PBMC, peripheral blood mononuclear cell; TFVdp, tenofovir diphosphate.
a b^1denotes the regression line slope for the log-transformed area under curve over 48 hours versus the log-transformed dose.
b Perfect dose proportionality is denoted by b^1 ¼ 1. Therefore, dose proportionality is declared if the 90% CI is within .64 and 1.36.
c Not applicable (NA) because of sparsely sampled data.
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tissue (222.3 µg*hr*g−1) than FGT tissue (17.6 µg*hr*g−1),
FTCtp values were 140 times higher in FGT tissue (15 094.3
pmol*hr*g−1) than colorectal tissue (108.2 pmol*hr*g−1). Con-
centration versus time profiles for blood and tissues are provid-
ed in Supplementary Figures 1 and 2, respectively.
Human Mucosal Tissue Endogenous Nucleotides
Although dATP concentrations were similar in vaginal and cer-
vical tissues (Figure 2A), dCTP concentrations were 50% lower
in vaginal versus cervical tissue (Figure 2B). Colorectal tissue
contained lower endogenous nucleotide pools as compared to
the FGT: dATP concentrations were 5 times lower (P < .05),
and dCTP concentrations were 5–11 times lower (P < .05). In
all tissues, dATP and dCTP concentrations were highly correlat-
ed (cervical tissue, Pearson r = 0.84; vaginal tissue, Pearson
r = 0.92; and colorectal tissue, Pearson r = 0.73; P < .0001). No
differences in PBMC or tissue dATP/dCTP concentrations
were noted between treatment arms, dosing groups, or sample
Figure 3. In vitro concentration versus response for TZM-bl cells and CD4+ T cells. TZM-bl and stimulated, primary CD4+ T cells were incubated for 24 hours in 0.03–35 µM
concentrations of tenofovir and emtricitabine. Intracellular active metabolite and endogenous nucleotide (EN) concentrations were quantified at the time of challenge with
human immunodeficiency virus type 1 (HIV-1JR-CSF; for TZM-bl cells) or pseudovirus with HIV-1JR-CSF envelope (for CD4
+ T cells). For TZM-bl cells, 34 samples were collected for
tenofovir diphosphate (TFVdp):deoxyadenosine triphosphate (dATP) measurement and 41 for emtricitabine triphosphate (FTCtp):deoxycytidine triphosphate (dCTP) measurement
across at least 2 independent experiments (values in 6 of 72 samples were below the limit of quantification [BLQ]). For CD4+ T cells, 14 samples were collected for TFVdp:dATP
measurement and 27 for FTCtp:dCTP measurement across at least 2 independent experiments (values in 2 of 42 samples were BLQ). Solid lines represent the median regression
line of the Emax model. The dashed reference line indicates 90% inhibition of human immunodeficiency virus (HIV) infection, and the dotted line represents 50% inhibition. The
50% effective concentration (EC50) ratio (±standard error [SE]) for TFVdp:dATP (A) was 0.010 ± 0.001 (P < .001), with a Hill slope (±SE) of 1.02 ± 0.09 (P < .001) in TZM-bl cells (○)
and 0.086 ± 0.011 (P < .001) with a Hill slope of 1.81 ± 0.39 (P < .001) in CD4+ T cells (▴). B, The EC50 ratio (±SE) for FTCtp:dCTP was 0.059 ± 0.004 (P < .001) with a Hill slope
(±SE) of 1.42 ± 0.11 (P < .001) in TZM-bl cells (○) and 0.022 ± 0.005 (P < .001) with a Hill slope of 1.88 ± 0.67 (P < .05) in CD4+ T cells (▴).
Figure 2. Tissue endogenous nucleotide concentrations plotted as median values (solid line within each box), 25th and 75th percentiles (box edges), and 10th to 90th
percentiles (whiskers) for 47 women. *P < .05. A, Median deoxyadenosine triphosphate (dATP) concentrations are 85% lower in colorectal tissue, compared with cervical
and vaginal tissues (P < .05; n = 47). B, Median deoxycytidine triphosphate (dCTP) concentrations in colorectal tissue are 90% lower than those in cervical tissue and 80%
lower than those in vaginal tissue (P < .001; n = 47).
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collection time. In the female genital and colorectal tissues, ra-
tios of the TFVdp concentration to the dATP concentration
(TFVdp:dATP) ranged from 0.00074 to 0.14 and 0.0014 to
5.9, respectively, and ratios of the FTCtp concentration to the
dCTP concentration (FTCtp:dCTP) ranged from 0.025 to 17
and 0.016 to 1.4, respectively.
PK Modeling
An 8-compartment model with 7 gastrointestinal transit com-
partments (Supplementary Figure 3) best fit the clinical trial
concentration data. Model parameters (Supplementary Table 1)
and goodness of fit have been previously reported [18]. A 1000-
subject Monte Carlo simulation was performed to simulate
TFVdp:dATP and FTCtp:dCTP in FGT and colorectal tissues
over the dosing interval for the first 10 daily doses and under
steady-state conditions for each drug alone and in combination.
TFVdp reached steady-state concentrations by dose 3 in FGT
tissue and by dose 9 in colorectal tissue. FTCtp reached
steady-state concentrations by dose 2 in FGT tissue and by
dose 6 in colorectal tissue.
In Vitro Concentration Versus Response
We investigated targets for protective efficacy against HIV infec-
tion in both a cell line and primary human cells. Figure 3 illus-
trates the best fit Emax parameters for active metabolite to
endogenous nucleotide concentration ratios and protection
from HIV infection. The estimated TFVdp:dATP EC90 was
0.086 in TZM-bl cells) and 0.29 in CD4+ T cells. The estimated
FTCtp:dCTP EC90 was 0.27 in TZM-bl cells and 0.07 in CD4
+ T
cells. Emax model parameters for culture medium drug concen-
tration and intracellular active metabolite versus percentage in-
hibition are provided in Supplementary Table 2. The TFVdp:
Figure 4. Time to protection and minimally effective preexposure prophylaxis (PrEP) dosing. Shown are pharmacokinetic (PK)/pharmacodynamic (PD) simulations for colo-
rectal tissue (A and B) and lower female genital tract (FGT) tissue (C and D). A and C, The percentage of the simulated population achieving the 90% effective concentration
(EC90) for tenofovir diphosphate (TFVdp):deoxyadenosine triphosphate (dATP), emtricitabine triphosphate (FTCtp):deoxycytidine triphosphate (dCTP), or combination ratios de-
rived from the in vitro PK/PD relationship in CD4+ T cells is plotted over the dosing interval for the first 10 daily doses of tenofovir disoproxil fumarate (TDF; dashed line),
emtricitabine (FTC; dotted line), or the fixed-dose combination (TDF plus FTC; solid line). B and D, The percentage of the population achieving these EC90 ratios at the end of the
dosing interval under steady-state conditions with 1–7 doses/week of TDF, FTC, or TDF plus FTC are stratified by tissue. We predict that the maximal percentage of the
population achieved EC90 ratios by the third daily dose of TDF plus FTC in colorectal and FGT tissues after beginning PrEP. Consistently using 7 doses/week of TDF plus
FTC will achieve EC90 ratios in 100% of the population in FGT and colorectal tissues. Only 65% of the population using 2 doses/week of TDF plus FTC achieve target exposure
in the FGT tissue, whereas ≥95% using 2 doses/week of either TDF or TDF plus FTC achieve target exposure in colorectal tissue.
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dATP and FTCtp:dCTP demonstrated synergy in TZM-bl cells
(c^ ± standard error, 0.63 ± 0.074; P < .001, where c^ , 1 indi-
cates synergy). A synergistic interaction was also noted between
TFV and FTC in CD4+ T cells (data not shown).
PK/PD Simulations
EC90 ratios derived from the more biologically relevant activat-
ed CD4+ T-cell Emax model were used as target efficacy exposure
for monotherapy simulations with TDF or FTC. The c^ ¼ 0:63
modeled a surface to describe all possible EC90 combination ra-
tios when using TDF plus FTC. To quantify the difference in
predictions produced by the 2 PD models, we simulated 1000
clinically relevant TFVdp:dATP and FTCtp:dCTP. The predict-
ed proportion of the population achieving target exposure dif-
fered by ≤2% between the 2 models.
In colorectal tissue, the maximal proportion of the popula-
tion (100%) achieved target exposure for efficacy after 3 daily
doses of the fixed-dose combination (Figure 4A). In FGT tissue,
the maximal proportion of the population (99%) achieved tar-
get exposure over the entire dosing interval after 3 daily doses of
the fixed-dose combination (Figure 4C). In colorectal tissue,
dosing twice/week with the fixed-dose combination achieved
target exposure in >95% of the population (in FGT tissue, this
dosing achieved target exposure in 65% of the population; Fig-
ure 4B and 4D).
To predict pericoital dosing effectiveness, we simulated the
colorectal tissue exposure achieved by the Ipergay dosing regi-
men (2 doses 2–24 hours before coitus, 1 dose 24 hours after
coitus, and 1 dose 48 hours after coitus) for TDF alone and
with FTC. When administered 2 and 24 hours before coitus,
Figure 5. Protection with pericoital preexposure prophylaxis (PrEP) dosing. Shown are pharmacokinetic (PK)/pharmacodynamic (PD) simulations for the Ipergay dosing reg-
imen (2 tablets 2–24 hours before coitus [solid vertical line], 1 tablet 24 hours after coitus, and 1 tablet 48 hours after coitus) for tenofovir disoproxil fumarate (TDF; solid line)
and the fixed-dose combination of TDF plus emtricitabine (FTC; dashed line). The percentage of the simulated population achieving the 90% effective concentration (EC90) of
tenofovir diphosphate (TFVdp):deoxyadenosine triphosphate (dATP), with or without FTC triphosphate (FTCtp):deoxycytidine triphosphate (dCTP), derived from the in vitro PK/PD
relationship in CD4+ T cells over 14 days following a single act of coitus in colorectal (A and B) and lower female genital tract (FGT) tissue (C and D). PK/PD simulations are
reported on the assumption that the first dose was administered 24 hours (A and C) or 2 hours (B and D) before coitus. We predict the maximal percentage of the population
achieving EC90 ratios in colorectal tissue over a 240-hour postcoital window is achieved by initiating the Ipergay dosing 24 hours before coitus. Dosing at 24 hours or 2 hours
before coitus did not appear to alter the percentage of the population achieving target exposure in the FGT tissue over a 72-hour postcoital window.
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TDF plus FTC achieved target exposure (at the time of coitus)
in approximately 81% and 98% of the population, respectively
(Figure 5A and 5B). Target exposure was sustained to 240 hours
after coitus. In the FGT, when administered 2 and 24 hours be-
fore coitus, TDF plus FTC achieved target exposure at the time
of coitus in 98% and 100% of the population, respectively (Fig-
ure 5C and 5D). The concentrations in the FGTwere short-lived
compared to colorectal tissue: <85% of the population had tar-
get exposure at 120 hours following coitus.
DISCUSSION
Phase 3 clinical trials evaluating daily oral TDF, with or without
FTC, for HIV PrEP have demonstrated mixed results in hetero-
sexual women [1, 3, 4, 19]. To understand this, we generated
comprehensive PK and biological data in vulnerable mucosal
tissues and evaluated effective drug exposure with different dos-
ing strategies. To our knowledge, this is the first biologically
complete model to predict effective PrEP dosing. This analysis
generated several important findings: (1) confirmation that TFV
and FTC have different tissue distribution characteristics, in
which TFV favors colorectal tissue and FTC favors FGT tissue;
(2) characterization of the ratio of the intracellular active metab-
olite concentration to endogenous nucleotide concentration as
an accurate PD target for nucleoside reverse transcriptase inhib-
itors (NRTIs), whereby endogenous nucleotides were found in
higher concentration in FGT tissue; and (3) evidence that this
PK/PD approach can be used to develop optimized TDF, with
or without FTC, PrEP dosing strategies and predict clinical trial
outcomes with different adherence patterns prior to the trials
being conducted.
Previously, Patterson et al described 100-fold higher TFVdp
concentrations in colorectal tissue, compared with FGT tissue,
with a single dose of TDF plus FTC [7]. Here, we investigated
50%–200% of the licensed treatment doses to develop a robust
PK model of TFVdp and FTCtp distribution. Our findings are
consistent with those of this previous report: TFVdp concentra-
tions overall were 10 times higher in colorectal tissue, while
FTCtp concentrations were 140 times higher in FGT tissue. Be-
tween-tissue differences in drug transport systems may explain
differential concentrations, yet blood flow to rectal and vaginal
mucosa is similar [20]. Drug transport by lymph fluid into tis-
sues has not been fully characterized. The lipid-rich lymph fluid
may not favorably transport hydrophilic compounds like TFV
and FTC [21, 22]. However, the leaky lymphatic endothelium
could provide an alternative mode of absorption in colorectal
tissue [23], possibly explaining the delayed peak we observed
in this tissue. We also found that dATP and dCTP concentra-
tions were 7 and 11 times lower, respectively, in colorectal tissue
as compared with FGT tissue. Therefore, not only were TFVdp
concentrations much higher in colorectal tissue, but the colo-
rectal intracellular environment favors TFV’s prophylactic
activity.
A significant limitation in determining PrEP concentration
targets for efficacy is the inability to easily measure the PK/
PD relationship in humans. HIV prevention models rely on ex-
trapolating data from cell culture systems, human tissue ex-
plants, or animal studies, each of which has limitations [24,
25]. Primate models use simian immunodeficiency virus or sim-
ian/human immunodeficiency virus, which may not mimic
HIV’s response to antiretrovirals [26]; antiretroviral exposure
in humanized mouse models may not match humans [26];
and endogenous nucleotides in ex vivo tissue explants deterio-
rate by ≥80% within 24 hours of isolation [27]. Although a ho-
mogenous cell population fails to represent the 3-dimensional
architecture and diverse microanatomy involved in transmis-
sion events, these models can be infected with HIV, can be ex-
posed to clinically relevant antiretroviral concentrations, and
can sustain endogenous nucleotide pools [28]. Since active me-
tabolite concentrations in isolated mononuclear rectal cells
strongly correlate with tissue homogenate concentrations [29],
we believe that using isolated target cells to generate concentra-
tion-effect relationships for NRTI prevention strategies is
reasonable.
A number of previous studies have highlighted the impor-
tance of endogenous nucleotides in NRTI efficacy [30–32].
Therefore, we postulated significant differences in tissue con-
centrations of endogenous nucleotide may affect the PK/PD re-
lationships for HIV prevention. Using primary (human CD4+ T
cells) and immortalized (TZM-bl cells) culture systems with a
clinically relevant HIV-1 challenge, we identified efficacy targets
for TFVdp and FTCtp relative to their competing endogenous
nucleotides (dATP and dCTP). Differences in the concentra-
tion-response relationship between in vitro systems were
noted. However, normalizing active metabolite to endogenous
nucleotide concentrations reduced the difference between
TZM-bl cell and CD4+ T cell EC90 ratio values by 70% (Supple-
mentary Table 2) and resulted in a difference of <2% in clinical
predictions between these model systems, highlighting the im-
portance of the endogenous nucleotide exposure.
Combining the mathematical PK mucosal tissue model with
the cellular target ratios, we determined that the maximal pro-
portion of the population achieved effective FGT and colorectal
concentrations after 3 doses of TDF plus FTC. Our data are con-
sistent with those of the Cell-PrEP study [33]. These data differ
from the Centers for Disease Control and Prevention guidelines,
which are built on extrapolations from PBMC data [34]. How-
ever, since they are based on tissue PK data, we believe they bet-
ter inform clinical usefulness. Importantly, we found that 2
doses/week of TDF, with or without FTC, achieved effective co-
lorectal concentrations in >95% of the population, which emu-
late iPrEx-OLE results (90% protection with 2–3 dose/week of
TDF plus FTC) [6].
To predict colorectal protection with pericoital oral dosing,
we evaluated the Ipergay dosing regimen [35]. When a double
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dose of TDF plus FTC is taken 24 hours before coitus and 2
doses are taken over 48 hours following coitus, we demonstrate
that >95% of the population achieves effective concentrations in
colorectal tissue at the time of and for ≥240 hours after coitus.
When administered 2 hours before coitus, concentrations in ap-
proximately 17% of the population are below the target for the
first 4 hours after coitus. However, this is likely an inconsequen-
tial delay, since it takes 4 hours for reverse transcription to occur
after HIV binds to cellular membranes [36]. These findings rea-
sonably emulate clinical trial data for this dosing regimen,
which demonstrated 86% efficacy in MSM [35].
Our data show that daily use of TDF plus FTC is required for
100% of the population to be protected from HIV infection with-
in the FGT. Our efficacy predictions are in agreement with the
Partners PrEP trial, which demonstrated 92% risk reduction
(95% CI, 19%–99%) when women taking TDF plus FTC for
PrEP had plasma drug concentrations consistent with very
high adherence [37]. We also simulated the Ipergay regimen
for the FGT. Using this approach, >95% of the population achieve
target exposure in FGT tissue at the time of and for 72 hours after
coitus. However, the effect is comparatively short lived, as by 120
hours following coitus <85% are still at target exposure. Admin-
istering TDF plus FTC 2 or 24 hours before coitus did not change
the proportion achieving target exposure in the FGT tissue across
this time frame. To match the percentage of the population
achieving target exposure in colorectal tissue with Ipergay dosing,
women would need to take 9 daily doses of TDF plus FTC follow-
ing coitus. These data suggest this may not be a strongly protec-
tive regimen for women vaginally exposed to HIV and are
consistent with recent preliminary reports from clinical trials in
which more women using intermittent dosing acquired HIV as
compared to those using daily dosing [38].
Our approach has certain limitations. First, our in vitro
methods necessitated the use of PHA/interleukin 2 stimulation,
which may increase the phosphorylation of NRTIs and endog-
enous nucleotides in CD4+ T cells [9].However, direct measure-
ment of active metabolites and normalization to endogenous
nucleotides helped minimize confounding. Although the expo-
sure-response relationship was defined under conditions of stat-
ic drug exposure, given the long intracellular half-lives of
TFVdp and FTCtp (approximately 48 and 39 hours, respective-
ly) [39, 40] marked fluctuation of active metabolite concentra-
tions in tissues is not expected and has not been identified.
The concentration data used to build the PK model was ob-
tained over 48 hours. However, there is precedent for making
steady-state drug exposure predictions from similarly developed
models [41]. Further, our predicted steady-state plasma concen-
trations were consistent with literature values, and our predicted
time to steady state in colorectal tissue (9 days for TFVdp) was
consistent with findings from previous reports [33]. The use of
homogenates of tissue biopsy specimens to measure mucosal
tissue drug concentrations assumes uniform distribution of
drug and endogenous nucleotide concentrations across the bi-
opsy specimen, which is unlikely [42]. However, isolating HIV
target cells from vaginal and cervical tissue biopsy specimens
has resulted in incomplete PK data sets, owing to small, incon-
sistent cell yields [39], and previous publications have demon-
strated linear relationship between isolated mucosal cells and
tissue homogenate concentrations [29].
Although we used PK data collected only from women, par-
ent and metabolite colorectal drug concentrations overlapped
with previously published data in men [7], suggesting that mu-
cosal tissue differences are driven primarily by the drugs’ distri-
bution characteristics rather than by inherent sex differences.
Since the risk of HIV transmission per act of unprotected recep-
tive anal intercourse does not differ between MSM and hetero-
sexuals [43], it is unlikely that biological differences alter HIV
infectability in male versus female colorectal tissue. Thus, we
believe it is reasonable to substantiate our colorectal model pre-
dictions with PrEP clinical trials results from MSM-only popu-
lations. Last, our population PKmodel was generated using data
from healthy volunteers in the absence of sexually transmitted
diseases or conditions causing inflammation in the lower gas-
trointestinal tract and FGT. Active metabolite and endogenous
nucleotide concentrations may be altered during mucosal tissue
inflammation [44], along with altered susceptibility to HIV in-
fection, and warrant further investigation.
In summary, this study is the first of its kind for HIV-
associated oral PrEP. By pairing phase 1 tissue concentration
data with in vitro systems of HIV infection, we created a predic-
tive population PK/PD model for PrEP that is consistent with
clinical trial outcomes. Here we demonstrate proof of concept
that a more complete characterization of the achievable and ef-
fective concentrations can be used to generate PK/PD models to
optimize drug dosing prior to the initiation of phase 3 trials and
to quantify the effect of incomplete adherence on protective ef-
ficacy. We believe this approach can be applied to other drugs
and combinations to inform clinical trial design and optimize
resources within the HIV prevention field.
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